Shukra Pharmaceuticals Limited

BSE: SHUKRAPHAR524632ISIN INE551C01044

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹79.85-0.11 (-0.14%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

Splits and bonuses

21 Mar 2025 · Split 10:1 (₹10 → ₹1)

52W high: ₹84.25
52W low: ₹26.30
Off 52W high: -5.22%
1M return: +13.83%
3M return: +141.31%
6M return: +137.51%
1Y return: +102.72%
20D avg volume: 7,37,325
50 DMA: ₹60.50
200 DMA: ₹41.84

Key ratios Consolidated

Market cap: ₹3,510 Cr
Current price: ₹79.85
52W high / low: ₹84.25 / ₹26.30
Face value: ₹1.00
P/E: 0.00
P/B: 38.92
EPS (TTM): ₹0.00
Book value / share: ₹2.05
ROE: —
ROCE: 31.70%
Operating margin: —
Net margin: —
Debt / equity: 0.06
Net debt: ₹-0.96 Cr
Interest cover: 27.41
Dividend yield: 0.01%
Dividend / share (TTM): ₹0.01
Payout: —
Cash conversion cycle: 172.4 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q4 FY25
Income statement
	23.52	6.32	39.13	—
	0.54	0.95	0.82	—
	24.06	7.27	39.95	—
	5.89	7.19	13.12	—
	1.25	6.99	3.20	—
	0.00	0.00	0.00	—
	4.39	0.37	2.65	—
	0.43	0.26	0.28	—
	1.08	1.01	0.84	—
	1.52	-0.69	2.22	—
	18.17	0.38	26.83	—
	0.00	0.00	0.00	—
	18.17	0.38	26.83	—
	5.21	2.10	4.85	—
	12.96	-2.02	20.36	—
	0.30	-0.04	0.47	—
Key metrics
	19.68	1.65	27.95	—
	83.70%	26.10%	71.40%	—
	55.10%	-32.00%	52.00%	—
	—	0.70%	—	—

Metric	FY26	FY25
Income statement
	56.73	—
	4.58	—
	61.31	—
	32.53	—
	19.45	—
	0.00	—
	7.04	—
	1.09	—
	3.44	—
	5.10	—
	28.79	—
	0.00	—
	28.79	—
	6.73	—
	22.06	—
	0.50	—
Key metrics
	33.32	—
	58.70%	—
	38.90%	—
	31.70%	—
	3.93	—
	0.18	—
	0.06	—
	-0.96	—
	172.4	—
Balance sheet
	117.44	—
	83.81	—
	5.98	—
	22.95	—
	13.90	—
	21.72	—
	10.06	—
	23.09	—
	5.02	—
	1.83	—
	3.19	—
	89.85	—
Cash flow
	3.93	—
	-14.14	—
	4.07	—
	0.00	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	23.52	6.30	39.13	5.88	5.39	13.27	10.58	5.55	3.18	10.88	18.89	24.64
	0.54	0.95	0.82	1.71	1.11	1.47	1.01	1.02	0.72	1.38	0.56	0.24
	24.06	7.25	39.95	7.59	6.50	14.74	11.59	6.57	3.90	12.26	19.45	24.88
	3.82	6.88	13.12	7.39	5.13	7.17	7.50	5.70	3.10	7.04	9.92	20.18
	0.00	6.69	3.20	10.81	-1.25	5.59	3.78	1.45	0.92	2.71	3.85	4.80
	1.25	0.00	0.00	0.00	2.02	0.00	—	0.86	—	—	3.43	10.94
	2.42	0.37	2.65	2.19	1.82	1.75	1.55	1.43	1.38	1.58	1.35	1.37
	0.43	0.26	0.28	0.28	0.27	0.27	0.15	0.11	0.06	0.07	0.07	0.06
	1.07	1.01	0.84	0.81	0.79	0.94	0.70	0.70	0.67	0.52	0.51	0.56
	1.44	0.70	2.22	2.10	1.48	2.44	1.14	1.08	0.97	—	0.72	0.50
	20.24	0.37	26.83	0.20	1.37	7.57	4.09	0.88	0.80	5.22	9.53	4.70
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	20.24	0.37	26.83	0.20	1.37	7.57	4.09	0.88	0.80	5.22	9.53	4.70
	5.21	2.09	4.85	-2.18	0.34	2.18	0.93	0.34	0.31	1.24	0.11	0.01
	15.03	-1.73	20.36	2.38	1.03	5.39	3.16	0.54	0.48	3.99	9.42	4.71
	0.34	-0.04	0.47	0.05	0.02	0.12	0.72	0.25	0.11	3.64	8.61	1.47
Key metrics
	21.74	1.64	27.95	1.29	2.43	8.78	4.94	1.69	1.53	5.81	10.11	5.32
	92.40%	26.00%	71.40%	21.90%	45.10%	66.20%	46.70%	30.50%	48.10%	53.40%	53.50%	21.60%
	63.90%	-27.50%	52.00%	40.50%	19.10%	40.60%	29.90%	9.70%	15.10%	36.70%	49.90%	19.10%
	—	0.70%	—	0.60%	—	11.30%	—	—	—	—	—	—
	336.40%	-52.50%	269.80%	5.90%	69.50%	22.00%	-44.00%	-77.50%	—	—	—	—
	1,359.20%	-132.10%	544.30%	340.70%	114.60%	35.10%	-66.50%	-88.50%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	74.83	56.71	32.59	74.57	58.83	20.49
	4.02	4.58	4.21	2.81	1.20	0.08
	78.85	61.29	36.79	77.39	60.03	20.57
	31.21	32.52	23.46	57.51	55.59	19.55
	20.70	19.45	11.75	13.38	11.35	11.08
	1.25	0.00	0.00	30.41	34.30	—
	7.63	7.04	6.11	5.65	4.89	4.90
	1.25	1.09	0.59	0.28	0.28	0.29
	3.73	3.44	3.00	2.05	1.84	1.66
	6.46	5.10	5.64	—	3.26	2.35
	47.64	28.77	13.34	19.88	4.44	1.02
	0.00	0.00	0.00	—	—	—
	47.64	28.77	13.34	19.88	4.44	1.02
	9.97	5.10	3.76	1.35	0.04	0.27
	36.04	22.05	9.58	18.54	4.41	0.75
	0.82	0.50	0.22	16.93	26.21	4.79
Key metrics
	52.62	33.30	16.93	22.21	6.56	2.97
	70.32%	58.70%	51.90%	29.80%	11.20%	14.50%
	48.16%	38.90%	29.40%	24.90%	7.50%	3.70%
	—	31.70%	20.00%	—	—	—
	115.09%	74.00%	-56.30%	26.80%	187.10%	—
	256.13%	130.20%	-48.30%	320.40%	488.00%	—
	—	3.15	5.18	—	—	—
	—	0.14	0.83	—	—	—
	—	0.06	0.07	—	—	—
	—	-0.90	4.17	—	—	—
	—	172.5	106.3	—	—	—
Balance sheet
	—	117.41	86.77	—	—	—
	—	83.75	65.43	—	—	—
	—	5.92	0.00	—	—	—
	—	22.95	8.77	—	—	—
	—	13.90	9.95	—	—	—
	—	—	23.64	—	—	—
	—	21.72	19.40	—	—	—
	—	10.06	9.22	—	—	—
	—	23.08	17.28	—	—	—
	—	5.02	4.17	—	—	—
	—	1.83	1.06	—	—	—
	—	3.19	3.11	—	—	—
	—	89.83	62.84	—	—	—
Cash flow
	—	3.15	7.92	—	—	—
	—	-14.18	-1.26	—	—	—
	—	4.83	-4.52	—	—	—
	—	0.00	2.74	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: -1.22%
Sales CAGR 5Y: —
Profit CAGR 3Y: +71.00%
Profit CAGR 5Y: —
Sales YoY (TTM): +115.09%
Profit YoY (TTM): +256.13%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 51.16%

Quarter	September 2026	June 2026
Promoter %	51.16%	51.16%

Holder	Type	Holding	Previous	Change
RENUKA YOGESH PARIKH	Public	19.11%	19.11%	0.00%
ANAR PROJECT PRIVATE LIMITED	Promoter Group	18.71%	18.71%	0.00%
YOGESH BIHARILAL PARIKH	Public	17.56%	19.06%	-1.50%
PARSHVA TEXCHEM INDIA PRIVATE LTD.	Promoter Group	17.38%	17.38%	0.00%
NAVKAR SURGICAL GUJARAT	Promoter Group	11.74%	—	—
DAKSHESH RAMESHCHANDRA SHAH	Promoter	1.11%	1.11%	0.00%
ANAR JAYESHBHAI PATEL	Promoter	0.99%	0.99%	0.00%
SUJAY JYOTINDRA MEHTA	Promoter	0.71%	0.71%	0.00%
PAYAL SUJAY MEHTA	Promoter	0.52%	0.52%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Shukra Pharmaceuticals Limited S	3,510	79.85	97.38	31.70%	+115.09% TTM	+256.13% TTM	+102.72%

Filings & corporate actions

Recent announcements

Reg 324 Nov 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Unaudited financial results for the quarter ended 30th September 20264 Nov 2026 · Result / Financial Results
Unaudited financial results for the quarter ended 30th September 20264 Nov 2026 · Board Meeting / Outcome of Board Meeting
The Board Meeting to be held on 03/11/2026 has been revised to 04/11/2026 The Board Meeting to be held on 03/11/2026 has been revised to 04/11/202623 Oct 2026 · Board Meeting / Board Meeting
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Un-Audited Financial ....22 Oct 2026 · Board Meeting / Board Meeting
Change of Name by MCA12 Oct 2026 · Company Update / Change of Name
Reg 74(5)10 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Allotment of Shares pursuant to conversion of Warrants6 Oct 2026 · Others / Outcome without intimation
Clarification from the Company6 Oct 2026 · Company Update / General
The Exchange has sought clarification from Shukra Pharmaceuticals Ltd on October 06, 2026 with reference to significant movement in price, in order to ensure that investors have latest ....6 Oct 2026 · Company Update / Clarification
Voting Results with Scrutinizer Report29 Sep 2026 · AGM/EGM / Postal Ballot
Voting Results and Scrutinizer''s Report29 Sep 2026 · AGM/EGM / AGM
Outcome of AGM28 Sep 2026 · AGM/EGM / AGM
Closure of Trading Window24 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Newspaper Publication23 Sep 2026 · Company Update / Newspaper Publication
Corrigendum to Post Ballot Notice22 Sep 2026 · AGM/EGM / Postal Ballot
ANNUAL REPORT5 Sep 2026 · Others / Reg. 34 (1) Annual Report
AGM NOTICE5 Sep 2026 · AGM/EGM / AGM
Update on Date of AGM3 Sep 2026 · AGM/EGM / AGM
Intimatation of Record Date for Dividend3 Sep 2026 · Corp Action / Dividend Updates
Allottment of Preference Shares2 Sep 2026 · Others / Outcome without intimation
Newspaper Publication31 Aug 2026 · Company Update / Newspaper Publication
Postal Ballot Notice27 Aug 2026 · AGM/EGM / Postal Ballot
AGM and Change of Name22 Aug 2026 · Board Meeting / Outcome of Board Meeting
Media Release17 Aug 2026 · Company Update / General
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/08/2026 ,inter alia, to consider and approve AGM17 Aug 2026 · Board Meeting / Board Meeting
Reg 30 NSE LIsting Done14 Aug 2026 · Company Update / General
Reg 30 Change of name in object14 Aug 2026 · Company Update / General
Reg 3014 Aug 2026 · Company Update / General
Media release14 Aug 2026 · Company Update / General
Newspaper Publication13 Aug 2026 · Company Update / Newspaper Publication
Quarterly Results June 30, 202612 Aug 2026 · Result / Financial Results
Quartely results June 30, 202612 Aug 2026 · Board Meeting / Outcome of Board Meeting
The Board Meeting to be held on 11/08/2026 has been revised to 12/08/2026 Date of Board Meeting to be held on 11/08/2026 has been revised to 12/08/20266 Aug 2026 · Board Meeting / Board Meeting
Shukra Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve To consider and approve ....30 Jul 2026 · Board Meeting / Board Meeting
The Board took on record and confirmed that, in accordance with the terms of the aforesaid Special Resolution and the applicable provisions of Chapter V of the SEBI ICDR Regulations, the ....14 Jul 2026 · Others / Outcome without intimation
Reg 74(5)6 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
EGM Voting Results6 Jul 2026 · AGM/EGM / EGM
EGM6 Jul 2026 · AGM/EGM / EGM
Closure of Trading Window23 Jun 2026 · Insider Trading / SAST / Closure of Trading Window

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 0.0100	21 Sep 2026	21 Sep 2026	—
Final Dividend - Rs. - 0.0100	18 Sep 2025	18 Sep 2025	—
Stock Split From Rs.10/- to Rs.1/-	21 Mar 2025	21 Mar 2025	—
Final Dividend - Rs. - 1.0000	23 Sep 2024	—	—

Board meetings

4 Nov 2026 Board Meeting - Financial Results
3 Nov 2026 Board Meeting - Financial Results
12 Aug 2026 Board Meeting - Financial Results
11 Aug 2026 Board Meeting - Financial Results